Sofinnova Partners

#ICYMI: HEPTA Medical, CEO Thomas Bancel recently had a captivating conversation with Erin Tallman from @Medical Expo, shedding light on Hepta Medical's groundbreaking microwave ablation probe, its recent U.S. Patent approval, and its potential to revolutionize lung cancer ablation procedures.   Checkout the piece to learn more: https://lnkd.in/eYScRBFz

Congratulations to Moon Surgical, a Sofinnova Partners MD Start portfolio company, on their two certifications: ISO 27001:2022 and SOC 2.  These accomplishments highlight Moon's dedication to data security, privacy, and compliance, empowering them to deliver actionable insights to healthcare providers while upholding the highest standards of data protection.   🔗 Learn more: https://lnkd.in/eQ8fPndY 

deepc, a Sofinnova Partners Digital Medicine portfolio company, has partnered with the Artificial Intelligence Centre for Value Based Healthcare to advance radiology AI across six NHS trusts. This collaboration aims to enhance patient care, diagnostic precision, and operational efficiency within UK healthcare.   To support this initiative, deepc has made four strategic hires in the UK to drive growth and expand its presence in the region.   deepc’s platform, deepcOS®, provides seamless access to over 75 globally leading, regulatory-approved AI solutions, streamlining workflows and supporting radiologists in their daily work.   🔗 Learn more: https://lnkd.in/eaXPf9d8 Simon Turner, Edward Kliphuis, Javier Nunez-Vicandi, Aishwarya Parthasarathy

Congratulations to Bioptimus, a Sofinnova Partners Digital Medicine portfolio company, on their collaboration with Proscia, a growing leading player in the digital pathology sector. This partnership aims to advance AI in scientific research and drug development to improve oncology patient care. By integrating Bioptimus’ H-optimus-0 into Proscia’s Concentriq Embeddings, Proscia users will accelerate AI model development, driving breakthroughs in precision medicine and therapeutic R&D in oncology. H-optimus-0 is the largest open-source AI foundation designed specifically for pathology. It excels at important tasks like finding cancer cells and spotting genetic problems in tumors, helping to advance research, drug development, and medical testing. 🔗: https://lnkd.in/eb_HEeB2 Edward Kliphuis, Simon Turner, Javier Nunez-Vicandi, Aishwarya Parthasarathy

BFMTV’s Good Morning Business featured Frederic Cren, CEO of Inventiva Pharma, a Sofinnova Partners portfolio company. In his interview with Laure Closier, they discussed Inventiva's recent €348 million fundraising—one of the largest in the industry—along with the company's ambition to develop treatments for fatty liver disease.   📺 You can watch the interview here: https://lnkd.in/dHqd5xFB

Congratulations to Noema Pharma, a company founded by Sofinnova Partners, which announced impressive Phase 2a study data for Allevia 1 (NOE-TTS-211), featuring NOE-105, a first-in-class investigational therapy for Tourette Syndrome. Noema was created in 2019 with a mission to make a meaningful difference in the lives of patients suffering from debilitating CNS disorders. Today, as a clinical-stage biotech company, Noema continues to advance a portfolio of transformative therapeutics, applying first-in-disease approaches to tackle neuroscience-based conditions with high unmet need. Their pipeline includes four active Phase 2 programs, addressing conditions like Trigeminal Neuralgia pain, Tuberous Sclerosis Complex seizures, Tourette syndrome, and vasomotor symptoms from menopause. The latest positive data strengthens Sofinnova’s belief in Noema’s potential and underscores the remarkable progress since its inception. Learn more: https://lnkd.in/exaxJ4Gj Antoine Papiernik, Ilise Lombardo

Congratulations to Qorium, a Sofinnova Partners Industrial Biotech portfolio company and a leader in cultivated bovine leather, on successfully scaling the production of their lab-grown leather using a proprietary tissue bioreactor. This milestone brings the company one step closer to commercialization.   Qorium is set to transform the leather industry with its highly efficient and sustainable manufacturing process: no methane emissions, significantly reduced water and chemical use compared to traditional leather.   This achievement marks a significant step forward for both science and sustainability, reflecting the growing demand from brands and consumers for ethical alternatives without compromising quality. 🔗 Learn more: https://lnkd.in/ekTMn9fq   Guillaume Baxter, Michael Krel, Joško Bobanović, Mary McCarthy, Mariam Cherifi, Anna Belousova, Gabriela Sachet Fernández, PhD

We’re delighted to welcome Agnès Pauquet as Sofinnova Partners’ Head of Human Resources. Agnès brings over 30 years of experience in human resources, having held senior roles at major financial institutions worldwide. Agnès’s appointment underscores Sofinnova’s dedication to its people and reaffirms its unwavering commitment to strengthening the strong, inclusive culture that has been central to its success. We look forward to working with Agnès to continue attracting and retaining top talent and driving the ongoing evolution of our organization. 🔗 Learn more: https://lnkd.in/e5Cg55Sd

Congratulations to Inventiva Pharma, a Sofinnova Partners Crossover portfolio company, on its successful €348 million raise, making it the largest fundraising by a biotech specializing in drug development in France. Since 2018, Sofinnova has played a crucial role in supporting Inventiva's growth and success. This fundraise, not only demonstrates the value of Sofinnova’s Crossover strategy but also highlights the trust and confidence US life sciences investors, who contributed 90% of this round, have in Inventiva. The strong support from our global network underscores the effectiveness of our Crossover strategy in enabling companies like Inventiva to secure the financing needed for their innovative drug development initiatives. Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs. Proceeds from financing will be primarily used to advance Inventiva’s Phase 3, NATiV3 clinical trial evaluating lanifibranor in patients with MASH. Read the press release to learn more: https://lnkd.in/eUgkHVNU Frederic Cren, Kinam Hong, M.D., MBA, CFA, Cédric Moreau, Joe Anderson, Jacques Theurillat, Claire Catherinet, PhD, Alexandra Abreu, Elliott Puttock, Ph.D.

Inventiva Pharma’s impressive €348 million fundraise was featured in Le Monde. The Sofinnova Partners portfolio company (since 2018) successfully raised one of the largest fundraisings in the industry – 90% of which came from American investors specializing in life sciences. This achievement highlights the strength of Inventiva's innovative drug development pipeline and the confidence placed in the company by both European and American investors. Inventiva is one of the rare French biotechs to be listed on the stock exchange in both Europe and the United States. The Dijon-based company is developing a treatment for liver disease. Learn more: https://lnkd.in/eBQxG-EB Kinam Hong, M.D., MBA, CFA Zeliha Chaffin